Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005–2008

Table 4

Multivariate-adjusted ORs for any AMD in relation to RASI treatment duration among RASI users.

	Any AMD		Early AMD		Late AMD
	OR (95% CI)		OR (95% CI)		OR (95% CI)
Per year	0.87 (0.78–0.98)	0.02	0.87 (0.77–0.99)	0.03	0.87 (0.73–1.05)	0.14
Long-term use^ǂ	0.23 (0.14–0.38)	<0.001	0.23 (0.14–0.37)	<0.001	0.25 (0.07–0.87)	0.03

^ǂLong-term use was defined as taking RASI for more than 5 years. Reference group: patients taking RASIs for less than 5 years. Adjusted for age, stroke history, cataract surgery history, heart disease, and HDL. OR: odds ratio; AMD: age-related macular degeneration; CI: confidence interval; RASI: renin-angiotensin system inhibitor; HDL: high-density lipoprotein.